5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Inclusion Criteria: * Aged 3 to \< 12 months * Diagnosis of AD fulfilling the diagnostic criteria of Seymour * AD affecting at least 5% total body surface area * Investigator's Global Assessment (IGA) score of 2 or 3, corresponding to mild-to-moderate disease at baseline * Informed consent Exclusion Criteria: * Phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic corticosteroids within 4 weeks * Topical tacrolimus or pimecrolimus within 2 weeks * Topical therapy (e.g., tar, topical corticosteroids) within 3 days * Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history of malignant disease * Active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox), and/or clinically infected AD * Failure to thrive (e.g., weight or height/length below the 5th percentile) or developmental abnormalities such as head circumference less than 5th and more than 95th percentile * Known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical corticosteroids * Clinical conditions other than AD that according to investigator can interfere with the evaluation